Open­ing new bat­tle­front with Gilead, GSK touts new Dova­to non-in­fe­ri­or­i­ty da­ta months af­ter first ap­proval

Glax­o­SmithK­line is giv­ing its best shot at ri­val­ing Gilead on its home turf with Dova­to, a 2-drug HIV reg­i­men ap­proved in Eu­rope just days ago fol­low­ing a re­cent FDA OK. And it’s strength­en­ing its case with a fresh slate of Phase III da­ta that shows the drug is just as good as triple ther­a­pies for pa­tients al­ready on treat­ment.

The take­away from the topline re­sults an­nounced to­day is sim­ple: When pa­tients switch from a TAF-con­tain­ing, 3-drug reg­i­men to Dova­to af­ter at least six months, they main­tain sim­i­lar rates of vi­ral sup­pres­sion to oth­ers who con­tin­ue the orig­i­nal treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER